Laurus Labs Q1 Review - Strong Performance Driven By Formulations: ICICI Direct
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Direct Report
Laurus Labs Ltd. reported robust Q1 FY22 results.
Revenue growth of 31.1% YoY to Rs 1278.5 crore in Q1, partially offset by other active pharmaceutical ingredients (down 43% YoY).
Revenues were mainly driven by 95.0% YoY jump in contract research and manufacturing services business to Rs 195 crore and strong traction in formulations to Rs 521 crore with growth of 48% YoY.
Antiretroviral revenue grew 23% YoY to Rs 413.3 crore while oncology API grew 16% YoY to Rs 59.2 crore.
Laurus Labs' Ebitda margins improved 235.7 basis points YoY to 30.9% while Ebitda grew 42% YoY to Rs 395.4 crore.
Profit after tax was up 40.5% YoY at Rs 241.4 crore for the quarter.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.